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SuStainable HealtH Care SyStemS: tHe role of tHeraPeutiC Value and 
Value baSed PriCing
Hulshof J.A.M.
Simon-Kucher & Partners, Bonn, Germany
It is a common perception that the cost of pharmaceutical care, driven by the price 
of medicines, is a major contributor to increasing public health care expenditure, 
the culprit of unsustainability of health care systems. This presentation shows how 
the net effect of value-based pricing of new, innovative treatments and competi-
tive pricing of older, often generic, products defeats that perception. The growth 
of pharmaceutical expenditure is, in fact, leveling off in most European countries, 
a trend that started even before the economic crisis of 2008. Value based pricing 
is an approach by which the pricing strategy is determined by therapeutic value, 
economic value and cost-effectiveness. Value based pricing requires a substan-
tial body of sophisticated evidence, generated throughout product development. 
Competitive pricing is an approach by which the pricing strategy of older products 
is defined relative to the price of direct competitors in order to maximize market 
share. Competitive pricing occurs in crowded markets with multiple equal or undif-
ferentiated treatment options. In recent years, competitive pricing has brought the 
price of many widely prescribed drugs significantly down. These two approaches 
to strategic pricing take place against the backdrop of tightening public financing 
rules that aim at ensuring financial sustainability of publicly financed health care 
systems. Consequence thereof is a two-tiered market access decision-making rou-
tine: for high-value/high-priced innovative treatments centralized decision-making 
based on value assessment with evidence, restricting them to a tightly characterized 
severely ill patient sub-population with low volume and/or a sales ceiling; versus 
local decision-making based on lowest (net) price for high-volume multisource 
products or equivalent single-source products, leading to significantly lower (net) 
prices than the originator at time of launch. Sustainable pharmaceutical care with 
openness towards innovation is therefore within reach.
PHP290
eConomiC eValuation in Portugal – eStabliSHment of tHe national 
HealtH teCHnology aSSeSSment SyStem (SinatS)
Cortegaça P., Silva F., Viana D., Ramos R., Martins  J.
INFARMED, I.P., Lisbon, Portugal
Economics is a social science that has a focus on allocating limited resources effi-
ciently. In health care is essential to invest properly, assuring access to health tech-
nologies with the best cost-effective profile, ensuring the sustainability of National 
Health Systems. In Portugal, the INFARMED – National Authority of Medicines and 
Health Products I.P., has been making economic evaluations of medicines for 15 
years, and is currently developing the National Health Technology Assessment 
System – SiNATS, of the utmost importance to the National Health System. 
Nowadays the assessment of the technologies (relative effectiveness assessment 
and cost-effectiveness) is focused on medicines, within the reimbursement process 
and the preliminary assessment to its acquisition by the National Health System’s 
Hospitals. Consequently, it is always done before the reimbursement decision, as 
a supporting tool to the decision itself. The purpose of this model is to guarantee 
a global system, and at the same time, extending it to new technologies besides 
medicines, e.g. medical devices. In these cases, the cost-effectiveness evaluation will 
be done through the whole life-cycle of that technology, affecting its price and use 
considering its real performance; instead of only its market entry. The INFARMED, 
by developing SiNATS, intends to contribute to minimize expenditures in health and 
the citizens’ life quality, in order to assure the National Health System’s sustain-
ability and efficient usage of public resources in health. Moreover, this system also 
aims to observe the technologies’ effectiveness and its usage, with the purpose of 
reducing wastes as well as to promote and award innovation and equal access to 
health technologies. This research intends to verify the applicability of the univer-
sal key principles of Health Technology Assessment Systems in SiNATS, in order 
to guarantee that the model achieves its proposing objectives. The study will be 
focused on the structure of system.
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market aCCeSS and reimburSement oPtionS for orPHan durg 
HoSPital only mediCineS in euroPe – one Size fitS all?
Vosgerau S.1, Paulus G.1, Plantoer S.2
1IMS Health, Munich, Germany, 2IMS HEALTH GmbH & Co. OHG, Munich, Germany
Orphan drugs are medicines used to the treat life-threatening or chronic diseases 
affecting very rare diseases. From April 2000 to October 2010, 720 drugs received 
orphan drug designation from the European Medicines Agency (EMA). Hereof, 63 
were granted marketing a marketing authorization. Since then - with an annual 
orphan drug sales volume of more than $6 billion - there has been a steady increase 
in applications for orphan designation with the Committee for Orphan Medicinal 
Products (COMP), averaging ten positive recommendations per month. Although 
central approval of orphan drugs covers 30 European countries, it does not neces-
sarily provide for national availability as each national authority has to agree to 
market access and reimbursement. Further, the hospital sector is known for its 
high diversity in terms of national access mechanisms and degree of centralization, 
exemplified by the Nordic Countries: In Denmark and Norway a highly centralized 
hospital sector prevails with one main hospital procurement agency (AMGROS in 
Denmark and LIS in Norway), while in Sweden and Finland several county councils 
are authorized to make decisions independently from each other. The objective of 
the present study is to identify and evaluate possible short cut routes to market 
access and reimbursement for orphan drug hospital only medicines (OD-HOM) in EU 
and further investigate country specific requirements for identified short cut routes 
to market access and reimbursement for OD HOM in EU as strategic options. A litera-
ture review and further desk research was performed. The following countries are 
included in the analysis: Nordic Countries, Germany, France, The Netherlands and 
Spain. The results of the ongoing OD-HOM research will be displayed as a summary 
challenges to overcome regarding the overall ethics system. Applying same ethics 
regulations or guidelines from interventional studies may not be the most adequate 
choice for observational studies.
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State of tHe art reSearCH in auStria: dexHelPP - deCiSion SuPPort 
for HealtH PoliCy and Planning: metHodS, modelS and teCHnologieS 
baSed on exiSting HealtH Care data
Zauner G.1, Popper N.1, Breitenecker F.2
1dwh GmbH, Vienna, Austria, 2Vienna University of Technology, Vienna, Austria
The Austrian health care system incurs costs of 30 billion/year, the bulk of the costs 
(77%) are publicly financed. Health policy and decision planning based on research 
evidence helps to tackle increasing costs. The urgent need for the evaluation of 
new health technologies, services, infrastructure, as well as for the development 
of improved technologies for the analysis, planning and control of health systems 
is met by DEXHELPP. Methods: Today, decision support in health care is usually 
based on evidence from studies of limited size, but not yet on the analysis of 
large volumes of routinely collected health care data. DEXHELPP is dedicated to 
filling the gap by combining academic excellence by research partners with profes-
sional implementation including knowledge of commercial partner institutions. 
By doing so special methods for statistical analysis, simulation and visualisation 
will be implemented as well as new methods for documentation and provid-
ing of k-anonymity for used individual data. For this task, existing cooperation 
schemes provide a firm substantial and conceptual knowledge base. All relevant 
fundamental technological competencies from academic and applied research 
are provided by the consortium, coming from universities, competence centres, 
and R&D SMEs. Results: Developed methods will help in (1) analysing the status 
quo, (2) making reliable prognoses, and (3) evaluating the consequences of inter-
ventions. A scientific research server with routine data in order to test developed 
methods will be run. The project covers all relevant areas within this complex pro-
cess, from data management via analysis and modelling through to user friendly 
presentation of results and quality assurance. Some of the most important actual 
decision-makers in Austria complete the consortium with application-oriented 
expertise. ConClusions: DEXHELPP focusses on the development on high inno-
vative technological methods. Future focus will lay on building up a network 
with more stakeholders to integrate those methods in national and international 
processes.
PHP287
ProPoSed framework for Patient and PubliC inVolVement in tHe Hta 
ProCeSS in ireland
Walsh C.
Trinity College Dublin, Montenotte, Ireland
The rationale for patient and public involvement (PPI) in the Health Technology 
Assessment (HTA) process has been widely documented. Engagement of patients or 
public in the process facilitates a broadening of scope and delineates a role for the 
patient as an ‘expert witness’ who has unique insight to living with an illness and 
the potential benefits/disadvantages (including side effects) that medical technol-
ogy may offer. Our objective was to explore the concept of practical and meaningful 
public participation in the HTA process and present a research protocol to propose 
a PPI framework applicable to the Irish context. A qualitative systematic literature 
review and concept analysis was used to identify key attributes relating to patient 
and public involvement. It is proposed that this knowledge will be supplemented 
through semi-structured interviews of key informants and a review of a purposive 
sample of HTA agency websites. Researchers, decision makers and policy makers 
will contribute to development and refinement a framework through a process of 
deliberation. Capturing the diverging perceptions of key informants will lead to the 
enhancement of the proposed framework. The role of the publics will be clarified, 
various levels and methods of PPI further defined. This research will explore the 
concept of PPI and suggest a study protocol for the development of a framework for 
PPI in the context of the Irish HTA process.
PHP288
Patient aCCeSS to life-SaVing mediCation; PreVenting StoCk-outS 
due to Parallel trade
Ratcliffe M.1, Mbanya Z.2, Gielen V.1, Sparrowhawk K.1
1PHMR Associates, London, UK, 2PHMR Associates, Newcastle Upon Tyne, UK
Manufacturers and suppliers of potentially life-saving drugs must ensure adequate 
supplies of in-date drug formulations for all markets across Europe. Failure to do 
so risks patient lives, but stock-outs have occurred even when a manufacturer has 
“over-supplied” a market with many times the amount of drug expected to meet 
local demand. These stock-outs have occurred as a result of parallel trade. In these 
cases, as little as a 10% variance on pack cost is enough to trigger parallel trade, 
which can result from price variations at launch across the EU and currency fluc-
tuations following launch. These situations form a useful series of case studies to 
determine supply chain issues leading to stock-outs. Based on this case study analy-
sis, a model is being developed to estimate the degree of exposure to risk of parallel 
trade and its associated potential cost to the manufacturer/supplier, and to patient 
access. The model identifies and quantifies trade flow patterns and key elements. 
Consequently, supply planning is possible based on essential metrics identified in 
the trade flow patterns. An allocation scheme to meet local needs is the key output 
of the model. The allocation scheme is applied to limit stock to the country to be 
in line with demand, plus a smaller variance (depending on local conditions) for 
that market compared to that previously applied. The model is intended for use in 
key EU markets (France, Germany, Italy,  The Netherlands, Spain, Italy, UK) as well 
as countries in Central and Eastern Europe. The model should help to optimise 
supply chain planning and operations, thereby minimising the risk of stock-outs. 
Consequently, all patients requiring specific, potentially life-saving drugs should 
have access to these treatments.
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patient’s involvement and better health outcomes. Improving service development 
and access to health advice with care experience are other adjuvant interventions. 
So patient’s participation is a key better care plan.
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turkiSH PubliC ProCurement SyStem for mediCal deViCeS:a guide for 
reimburSement PoliCy?
Seyhun O., Can H., Erdol S., Erdogan Ciftci E.
Medtronic, Inc., Istanbul, Turkey
In 2008, Public Procurement Law (PPL) was amended to implement and regulate 
e-Procurement in Turkey. Non-private, public purchaser hospitals are obliged to 
enter tender results of their medical device purchases into e-procurement system 
(EPS) to be eligible for a reimbursement by the Social Security Institution (SSI) in 
Turkey. Objectives of this research are to examine the impact of the EPS that is 
currently being used for medical device purchases in Turkey since 2011; and to 
investigate how the system is being used to define ceiling prices for reimbursement, 
concurrently assessing the quality and quantity of data uploaded by hospitals. EPS 
data is downloaded on a GMDN basis from Turkish National Database for Medical 
Devices, (TITUBB) which is an e-catalogue system that was launched to provide bar-
code level product registration, search and the e-procurement results. In accordance 
with the objectives, assessment is conducted on more than ten GMDNs and results 
are utilized to see the effect of EPS on pricing, comparing the prices on officially 
published SSI positive lists. Our study shows that a lowest price detected on EPS 
could be set as the reimbursement price, as was the case for the product; aortic stent 
graft, contralateral limb, where a defined SSI positive list price was reduced after 
determination of a lower price on EPS, on account of  a mispriced tender record. 
An extrapolation while searching out the reimbursement prices is needed instead 
of SSI’s calculations based on merely a retrospective and detection of lowest price 
practice. Effectiveness of this policy depends on resolving the weaknesses of EPS 
data in terms of quality and quantity; a misdated tender or a mispriced product 
could be a ground for an erroneous price setting and tenders that are not recorded 
at all or deferred might lead to incomplete EPS data to define reimbursement prices.
diSeaSe-SPeCifiC StudieS
mental HealtH – Clinical outcomes Studies
PmH1
tHe riSk of metaboliC diSorderS in PatientS treated witH aSenaPine 
or olanzaPine: a real world data Study ConduCted in italy  
and SPain
Maina G.1, Ripellino C.2, Pegoraro V.2, Caresano C.3
1University of Turin, Turin, Italy, 2CSD Medical Research S.r.l., Milan, Italy, 3Lundbeck Italia  
S.p.A., Milan, Italy
objeCtives: Second-generation antipsychotic drugs, knows as Atypical 
Antipsychotics, have a better tolerability than conventional antipsychotics but it 
has reported that its usage lead to a substantial weight gain, an increase risk of 
dyslipidemia and type 2 diabetes mellitus. In this article authors assessed the risk 
of metabolic adverse events associated with Asenapine in comparison with those 
associated with Olanzapine by studying real world data. Methods: The study was 
a retrospective analysis based on data extracted from Italian and Spanish Cegedim 
Stategic Data Longitudinal Patient Data databases. Patients were divided in two 
cohorts (Asenapine and Olanzapine) according to the inclusion criteria and data 
from these patients were analyzed starting from 2009 up to 2013. Diabetes and 
dyslipidemia registrations have been searched in order to assess the risk of develop-
ing metabolic adverse events. Results: The retrospective analysis showed a lower 
risk of developing type 2 diabetes and dyslipidemia associated with Asenapine 
treatment in comparison with Olanzapine. Scenario analyses supported the robust-
ness of the results. ConClusions: Asenapine is associated with a lower risk of 
metabolic adverse events than Olanzapine, demonstrating a better safety profile 
with regard to metabolic effects.
PmH2
effiCaCy of tHe PHoSPHorylated tau P181 for tHe alzHeimer’S diSeaSe 
dementia - a SyStematiC reView and meta analySiS
Mo J.
National Evidence-based Health Care Collaborating Agency & Inha University, SEOUL,  
South Korea
objeCtives: The purpose of this study was to apply a systematic review of the 
literature to evaluate the diagnostic effectiveness of the Phosphorylated tau p181 
for the Alzheimer’s disease dementia. Methods: A systematic literature review 
was used to evaluate the effectiveness of of the Phosphorylated tau p181 for the 
Alzheimer’s disease dementia. The Scottish Intercollegiate Guidelines Network 
(SIGN) tool was used by two evaluators to independently evaluate the quality of the 
ten studies. The literature review covered from October 27, 1946 to October 22, 2013, 
and eight domestic databases including KoreaMed and foreign databases includ-
ing Ovid-MEDLINE, EMBASE, and Cochrane Library were used. Results: A total of 
9studies (9 diagnostic evaluation studies) were identified to evaluate Phosphorylated 
tau. Theeffectiveness of this test was evaluated based on diagnostic accuracy. The 
diagnostic accuracy for identifying AD of ELISA was high (pooled sensitivity, 0.843 
(95% CI 0.818-0.867); pooled specificity, 0.799 (95% CI 0.768-0.828); summary receiver 
operating characteristic area under the curve 0.9082±0.0236. Primary criteria for 
inclusion were valid studies on (i) patients with mild cognitive impairment with 
confirmed or suspected AD and non-AD dementia, and (ii) assessment of tau levels 
using appropriate comparative tests. ConClusions: Evaluated CSF Phosphorylated 
tau levels are of potential utility in the differential diagnosis of AD versus non-AD 
dementias and healthy controls.
of options and requirements by country. The evaluation of market access options for 
OD-HOM can ease market access and reimbursement and influence international 
launch sequences of innovative orphan drugs.
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CoSt and duration of regulatory ProCeSS in an obSerVational 
Study in euroPe and uSa
Ori A., Fiori G.G., Fernandez S., Longo D., Simoni L.
MEDIDATA SRL, MODENA, Italy
objeCtives: Despite the growing interest in observational studies, there is any 
defined regulatory process unlike clinical trials, which have a defined one. Currently, 
international observational studies have to deal with each county regulatory process 
that means to face times and costs very heterogeneous and not regulated yet by 
the EU. Here we report the experience of MediData in international observational 
study conduct. Methods: The start-up process in 7 countries was analyzed as for 
regulatory process in terms of time and costs. Results: In Europe the faster regu-
latory process takes 12 weeks (Turkey) and the slowest one takes almost twice as 
long (Italy 24 weeks), while in the USA they spend almost 16 weeks to conclude the 
whole process. Usually times and costs have an inverse relationship, but the observa-
tional studies analyzed shows that the second cheaper country is Turkey, that comes 
after France where the process is free. Another example of this variety is the case of 
Spain and France in the same duration of the process have a difference of spending 
of 12000 € . ConClusions: These duration and spending really differentiated 
have a huge impact on the observational study conduction. Especially at the inter-
national level, we might run into sponsored studies which could be conducted in 
countries with cheaper or faster regulation processes, with the real risk of a selection 
bias of the sites and, therefore, a very partial collection of data. Inevitably, the result 
will be unrepresentative epidemiological data. It’s very important to have a pan-Euro-
pean regulation that allows the observational study conduction in an homogenous 
and aligned way and also to have complete and representative epidemiological data.
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aCCeSS to orPHan drugS in franCe: tHe CaSe of SikloS for tHe 
treatment of SiCkle Cell Syndrome before tHe CounCil of State
Murteira S.1, El Hammi E.2, Kornfeld A.3, Toumi M.4
1Lundbeck Japan KK, Tokoyo, Japan, 2Evidenz, Tunis, Tunisia, 3Creativ-Ceutical, Paris, France, 
4University of Marseille, Marseille, France
bACkgRound: Hydroxycarbamid is an antineoplastic molecule commercialized 
since 1968 in France under the name Hydrea®. In the absence of an alternative 
licensed drug for the treatment of Sickle Cell Syndrome (SCS), Hydrea® has been rou-
tinely used off-label for over 15 years in this indication. In 2007, Siklos® became the 
first licensed orphan drug indicated in the symptomatic treatment of SCS. However, 
during the pricing and reimbursement procedures, the French Transparency 
Committee decided to compare Siklos® to Hydrea® and as such Siklos® was evalu-
ated as bringing a weak additional benefit (ASMR IV) which had a major impact on 
the price given by the French Economic Committee on Health Care Products (CEPS). 
The manufacturer of Siklos® entered in litigation with the CEPS and after a long 
legal procedure, the French Council of State issued two orders by way of interlocu-
tory procedures suspending the decision of the drug price setting and determining 
the minimal threshold under which Health Authorities could not set the price of 
this drug. disCussion: The negative assessment of the French HTA could have set 
a precedent for future evaluations of orphan or pediatric medicines issued from 
drug repurposing. These decisions are unique in the history of the Council of State’s 
jurisprudence on several aspects: it was an unprecedented case where a CEPS deci-
sion is overturned by the Council of State and the first time that a judicial decision 
provides guidance on the price level for a pharmaceutical drug in France. This case 
law has also the consequence to enlarge the criteria taken into account by the CEPS 
in new drug price setting, especially for orphan drugs. ConClusion: Siklos® case 
law provided a new legal ground that is in contradiction with available regulation 
and practice and opens the way for future legal challenges to the CEPS decisions.
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Patient’S PartiCiPation in imProVement of HealtH related outComeS: 
tHe better Care Plan
Singh A.1, Khera K.1, Rana R.2, Chauhan S.3
1Manipal College of Pharmaceutical Sciences, Manipal, India, 2R.M. Medical College & Hospital, 
Chennai, India, 3KLE’s College of Pharmacy, Belgaum, India
objeCtive: Patient’s involvement in their health care is important to improve qual-
ity, efficacy and better patient care. It is a strategy to achieve improved health 
outcomes and lower costs. A main objective of the discussion is focused on “how 
to inform, encourage and educate the patient to participate in their health care 
decisions?” The purpose of the discussion also centered on the various patients 
focused interventions required to improve the health care outcomes by patient’s 
participation. bACkgRound: All patients want the information about the disease 
and complications they have, but not all want to involve in decision making. Most of 
the patients preferred to leave the final decision on doctors/clinicians. Engagement 
of patients in health care and decision making would improve the health outcomes 
and lowering the cost of therapy or treatment. disCussion: Health care is a com-
plicated system to patients; they struggle to understand their medical conditions 
and services. All patients must have to know about basic health information and 
treatment options. This would be possible by encouraging patient’s to play an active 
role in their health care that could improve health outcomes, efficiency and quality. 
Patient’s participation and engagement are based on patient activation which refers 
to understanding, ability, health literacy and willingness of patient to manage his or 
her health and care. Patients can participate at different levels as direct care or their 
preference in treatment plan and/or in policy making for future recommendations. 
Patient focused interventions are discussed as companion to patient’s participation 
or engagement. Improvement in health literacy, patient safety, improvement in self 
care and clinical decision making are four primary interventions which promote the 
